Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2009

01-01-2009 | Research Paper

Influence of diet on metastasis and tumor dormancy

Author: Ann F. Chambers

Published in: Clinical & Experimental Metastasis | Issue 1/2009

Login to get access

Abstract

Tumor metastasis is responsible for most cancer deaths, and can occur after long periods of tumor dormancy. Information learned from experimental studies on tumor metastasis and dormancy is shedding light on mechanisms responsible and possible therapeutic approaches. ‘Seed’ (the cancer cell) and ‘soil’ (the microenvironment of the secondary organ) factors contribute to metastatic outcome. This review considers the possibility that various dietary components may affect both ‘seed’ and ‘soil’ compartments, thereby influencing the growth of metastases, and discusses an experimental study on dietary genistein that illustrates this concept. While studies on human diet are complex, the possibility that relatively non-toxic dietary intervention strategies could impact on metastasis and patient survival is attractive and worthy of further study in appropriate experimental models of metastasis and tumor dormancy.
Literature
1.
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRef
2.
3.
Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921–930PubMedCrossRef
4.
5.
Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5:1744–1750PubMed
6.
Naumov GN, MacDonald IC, Chambers AF et al (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11:271–276PubMedCrossRef
7.
Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5:1779–1787PubMed
8.
Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153PubMedCrossRef
9.
Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19:558–563PubMed
10.
Meng S, Tripathy D, Frenkel EP et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162PubMedCrossRef
11.
Goss PE (2007) Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 105(1):45–53PubMedCrossRef
12.
Pritchard KI, Goss PE, Shepherd L (2006) The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies. Breast 15(1):S14–S20PubMedCrossRef
13.
Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRef
14.
Briest S, Wolff AC (2007) Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Rev Anticancer Ther 7:1243–1253PubMedCrossRef
15.
Weiss L (1992) Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis 10:191–199PubMedCrossRef
16.
Fokas E, Engenhart-Cabillic R, Daniilidis K et al (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26:705–715PubMedCrossRef
17.
Ribatti D, Mangialardi G, Vacca A (2006) Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med 6:145–149PubMedCrossRef
18.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef
19.
Chambers AF, MacDonald IC, Schmidt EE et al (2000) Clinical targets for anti-metastasis therapy. Adv Cancer Res 79:91–121PubMedCrossRef
20.
Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101PubMed
21.
Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:99–101
22.
Kang Y (2006) New tricks against an old foe: molecular dissection of metastasis tissue tropism in breast cancer. Breast Dis 26:129–138PubMed
23.
Reddi AH, Roodman D, Freeman C et al (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18:190–194PubMedCrossRef
24.
Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRef
25.
Minn AJ, Gupta GP, Padua D et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104:6740–6745PubMedCrossRef
26.
27.
Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524PubMedCrossRef
28.
Gupta GP, Minn AJ, Kang Y et al (2005) Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70:149–158PubMedCrossRef
29.
Massague J (2003) New concepts in tissue-specific metastases. Clin Adv Hematol Oncol 1:576–577PubMed
30.
Buschemeyer WC 3rd, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52:331–343PubMedCrossRef
31.
32.
McTiernan A (2005) Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 19:871–881; discussion 881–872, 885–876
33.
Carmichael AR, Bates T (2004) Obesity and breast cancer: a review of the literature. Breast 13:85–92PubMedCrossRef
34.
Prentice RL, Willett WC, Greenwald P et al (2004) Nutrition and physical activity and chronic disease prevention: research strategies and recommendations. J Natl Cancer Inst 96:1276–1287PubMed
35.
Gong Z, Agalliu I, Lin DW et al (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 109:1192–1202PubMedCrossRef
36.
Carmichael AR (2006) Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 113:1160–1166PubMedCrossRef
37.
38.
Key TJ, Appleby PN, Reeves GK et al (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218–1226PubMed
39.
Wasserman L, Flatt SW, Natarajan L et al (2004) Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors. Int J Obes Relat Metab Disord 28:49–56PubMedCrossRef
40.
Mulligan AM, O’Malley FP, Ennis M et al (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39–47PubMedCrossRef
41.
DeLellis Henderson K, Rinaldi S, Kaaks R et al (2007) Lifestyle and dietary correlates of plasma insulin-like growth factor binding protein-1 (IGFBP-1), leptin, and C-peptide: the Multiethnic Cohort. Nutr Cancer 58:136–145PubMed
42.
Jenab M, Riboli E, Cleveland RJ et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition. Int J Cancer 121:368–376PubMedCrossRef
43.
Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17:328–336PubMedCrossRef
44.
Irwin ML, McTiernan A, Bernstein L et al (2005) Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev 14:2881–2888PubMedCrossRef
45.
Goodwin PJ, Ennis M, Pritchard KI et al (2002) Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 74:65–76PubMedCrossRef
46.
Pierce JP, Stefanick ML, Flatt SW et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25:2345–2351PubMedCrossRef
47.
Cotterchio M, Boucher BA, Kreiger N et al (2008) Dietary phytoestrogen intake-lignans and isoflavones-and breast cancer risk (Canada). Cancer Causes Control 19:259–272PubMedCrossRef
48.
Chlebowski RT, Blackburn GL, Thomson CA et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98:1767–1776PubMed
49.
Thiebaut AC, Schatzkin A, Ballard-Barbash R et al (2006) Dietary fat and breast cancer: contributions from a survival trial. J Natl Cancer Inst 98:1753–1755PubMed
50.
Knoops KT, de Groot LC, Kromhout D et al (2004) Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. Jama 292:1433–1439PubMedCrossRef
51.
52.
Fernandez E, Gallus S, La Vecchia C (2006) Nutrition and cancer risk: an overview. J Br Menopause Soc 12:139–142PubMedCrossRef
53.
Serra-Majem L, Roman B, Estruch R (2006) Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 64:S27–S47PubMedCrossRef
54.
McCarty MF, Block KI (2006) Toward a core nutraceutical program for cancer management. Integr Cancer Ther 5:150–171PubMedCrossRef
55.
He X, Liu RH (2006) Cranberry phytochemicals: isolation, structure elucidation, and their antiproliferative and antioxidant activities. J Agric Food Chem 54:7069–7074PubMedCrossRef
56.
Suffredini IB, Varella AD, Younes RN (2006) Cytotoxic molecules from natural sources: tapping the Brazilian biodiversity. Anticancer Agents Med Chem 6:367–375PubMedCrossRef
57.
Tan G, Gyllenhaal C, Soejarto DD (2006) Biodiversity as a source of anticancer drugs. Curr Drug Targets 7:265–277PubMedCrossRef
58.
Heinrich M, Bremner P (2006) Ethnobotany and ethnopharmacy – their role for anti-cancer drug development. Curr Drug Targets 7:239–245PubMedCrossRef
59.
60.
Duthie SJ (2007) Berry phytochemicals, genomic stability and cancer: evidence for chemoprotection at several stages in the carcinogenic process. Mol Nutr Food Res 51:665–674PubMedCrossRef
61.
Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19–34PubMedCrossRef
62.
63.
El Touny LH, Banerjee PP (2007) Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun 361:169–175PubMedCrossRef
64.
Duffy C, Perez K, Partridge A (2007) Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 57:260–277PubMedCrossRef
65.
Vantyghem SA, Wilson SM, Postenka CO et al (2005) Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res 65:3396–3403PubMed
66.
Mukherjee AK, Basu S, Sarkar N et al (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8:1467–1486PubMed
67.
So FV, Guthrie N, Chambers AF et al (1997) Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett 112:127–133PubMedCrossRef
68.
So FV, Guthrie N, Chambers AF et al (1996) Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26:167–181PubMedCrossRef
69.
Ferguson PJ, Kurowska EM, Freeman DJ et al (2006) In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutr Cancer 56:86–94PubMedCrossRef
70.
Ferguson PJ, Kurowska E, Freeman DJ et al (2004) A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr 134:1529–1535PubMed
71.
Martin JH, Crotty S, Nelson PN (2007) Phytoestrogens: perpetrators or protectors? Future Oncol 3:307–318PubMedCrossRef
72.
Messina M, McCaskill-Stevens W, Lampe JW (2006) Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 98:1275–1284PubMedCrossRef
73.
74.
Duffy C, Cyr M (2003) Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt) 12:617–631CrossRef
75.
Power KA, Thompson LU (2007) Can the combination of flaxseed and its lignans with soy and its isoflavones reduce the growth stimulatory effect of soy and its isoflavones on established breast cancer? Mol Nutr Food Res 51:845–856PubMedCrossRef
76.
Rae JM, Ramus SJ, Waltham M et al (2004) Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21:543–552PubMedCrossRef
77.
Rae JM, Creighton CJ, Meck JM et al (2007) MDA-MB-435 cells are derived from M14 melanoma cells – a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19PubMedCrossRef
78.
Ellison G, Klinowska T, Westwood RF et al (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299PubMedCrossRef
Metadata
Title
Influence of diet on metastasis and tumor dormancy
Author
Ann F. Chambers
Publication date
01-01-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9164-4

Other articles of this Issue 1/2009

Clinical & Experimental Metastasis 1/2009 Go to the issue

Research Paper

Tumor dormancy due to failure of angiogenesis: role of the microenvironment

EditorialNotes

Editorial introduction

Review

Epigenetic contributions to cancer metastasis

Research Paper

Introduction to special issue on ‘epigenetic and physiological regulation of metastasis’

Review

Three-dimensional context regulation of metastasis

Research Paper

The tumor microenvironment and metastatic disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits